NDA 021425 · Bayer Hlthcare
Ultravist (Pharmacy Bulk)
Iopromide · Injection
Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Sep 20, 2002
Approved uses
3
Original approval plus efficacy supplements
Registered trials
8
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 25, 2023 Supplement 36 · Efficacy LetterLabel
- Jun 23, 2010 Supplement 17 · Efficacy LabelLetter
- Sep 20, 2002 Original approval · Type 3 - New Dosage Form LetterLabelReview
3 products under this application
- ULTRAVIST (PHARMACY BULK) · IOPROMIDE 62.3% · INJECTABLE, INJECTION · Prescription
- ULTRAVIST (PHARMACY BULK) · IOPROMIDE 76.9% · INJECTABLE, INJECTION · Prescription
- ULTRAVIST (PHARMACY BULK) · IOPROMIDE 49.9% · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Iopromide" as an intervention, any sponsor and status, largest first.
- A Safety Comparison of Iopromide and Iodixanol in Renal Impaired PatientsPivotal-lookingCompleted
Chinese PLA General HospitalAcademic, hospital or other
NCT00926562 · 592 participants · Start Feb 2009 · Primary completion Dec 2010
Drug: Iopromide (Ultravist); Iodixanol (Visipaque) · For: Kidney Failure, Chronic
Sites: Beijing, China; Zhengzhou, China; Wuhan, China · 19 sites in all
- Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT AngiographyPivotal-lookingCompleted
GuerbetIndustry
NCT01255722 · 468 participants · Start Nov 2010 · Primary completion Sep 2012
Drug: iobitridol; iopromide and 1 more · For: Coronary Artery Disease
Sites: Angers, France; Brest, France; Le Plessis-Robinson, France · 23 sites in all
- Ultravist: Safety and Efficacy in Computed Tomography of Head and BodyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00244140 · 435 participants · Start Oct 2005 · Primary completion Apr 2008
Drug: Iopromide 370 mg I/mL; Iopromide 300 mg I/mL · For: Computed Tomography; Diagnostic Imaging
Sites: Tucson, Arizona; Miami, Florida; Tallahassee, Florida · 23 sites in all
- Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)Pivotal-lookingCompleted
Ospedale San DonatoAcademic, hospital or other
NCT00827788 · 432 participants (planned) · Start Dec 2008 · Primary completion Apr 2010
Drug: Iodixanol; Iopromide · For: Contrast Induced Nephropathy; Acute Myocardial Infarction
Sites: Arezzo, Italy
- Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus IopromidePivotal-lookingCompleted
Seoul National University Bundang HospitalAcademic, hospital or other
NCT00823628 · 420 participants (planned) · Start Feb 2009 · Primary completion May 2010
Drug: contrast agent (iopromide); contrast agent (iodixanol) · For: Chronic Renal Insufficiency; Coronary Angiography
Sites: Seongnam-si, South Korea
- Renal Toxicity of Iodixanol and Iopromide in Patients With Renal DysfunctionPivotal-lookingStatus unknown
Yong HuoAcademic, hospital or other
NCT01580046 · 200 participants (planned) · Start Apr 2012 · Primary completion Dec 2013
Drug: iodixanol; iopromide · For: Kidney Failure, Chronic
Sites: Hefei, China; Beijing, China; Fuzhou, China · 19 sites in all
GE HealthcareIndustry
NCT03631771 · 0 participants · Start Mar 2022 · Primary completion Aug 2024
Drug: Iohexol; Iodixanol and 2 more · For: Hypothyroidism
GE HealthcareIndustry
NCT00335101 · 0 participants · Start Jun 2006
Drug: Iodixanol, Ioversol, Iopromide · For: Coronary Artery Disease (CAD); Renal Impairment; Diabetes Mellitus
Sites: Princeton, New Jersey; Munich, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Enhanced external counterpulsation: A new method to alleviate contrast-induced acute kidney injury.
Zhang X, Yao C, Xiao Q, et al. · Contemp Clin Trials 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Iopromide and Iodixanol in the Development of Postoperative Contrast Nephropathy in Patients with Renal Insufficiency: A Meta-Analysis.
Feng Y, Qiu G, Xu C, et al. · J Healthc Eng 2022 · Meta-Analysis, Retracted Publication
- Comparative long-term efficacy and safety of two paclitaxel-coated balloons with different coating strategies for the treatment of drug-eluting coronary stent restenosis.
Koch T, Lenz T, Rheude T, et al. · Catheter Cardiovasc Interv 2024 · Comparative Study, Multicenter Study
- Double-blind study of a new nonionic contrast agent for digital subtraction arteriography.
Weiss JP, McLean GK, Modic MT, et al. · Invest Radiol 1994 · Clinical Trial, Comparative Study
- [Plasma histamine liberation after the application of nonionic contrast media].
Weiss HD, Jansen O, Schallock J, et al. · Rofo 1989 · Clinical Trial, Comparative Study
- Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
Zhang J, Jiang Y, Rui Q, et al. · Medicine (Baltimore) 2018 · Meta-Analysis, Review
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.